Floatz logo

Thiotepa

Common Variable Immune Deficiency

University of FloridaSmall moleculePhase 2Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Common Variable Immune Deficiency cohort.

Asset / SponsorPhaseRating
Conestat Alfa
IMMUNOe Research Centers
Phase 4BB
HUMAN IMMUNOGLOBULINS
Grifols Therapeutics LLC
Phase 3B
Fludarabine
Washington University School of Medicine
Phase 2CCC
IMMUNOGLOBULIN G1 (HUMAN-RAT MONOCLONAL CAMPATH-1H .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD52), DISULFIDE WITH HUMAN-RAT MONOCLONAL CAMPATH-1H LIGHT CHAIN, DIMER
Paul Szabolcs
Phase 2CCC
Evomela
Paul Szabolcs
Phase 2CCC

View all 19 →

Same molecule, other indications

Thiotepa is also rated in:

graft versus host diseaseDormant
BBB
Indicative ·
73 / 100
View asset →
myelodysplastic/myeloproliferative neoplasmDormant
BBB
Indicative ·
72 / 100
View asset →
juvenile myelomonocytic leukemiaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →